Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621
This examiner grants 63% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17292881 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Non-Final OA | Novartis AG |
| 18001316 | COMPOSITIONS, METHODS OF TREATING AND PREVENTING FUNGAL INFECTIONS, AND METHODS OF INHIBITING PRP8 INTEIN EXPRESSION | Non-Final OA | The Board of Regents of the University of Texas System |
| 17789047 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | Final Rejection | New York University |
| 17595098 | NOVEL MATERIAL FOR SKIN WOUND CLOSURE AND SCAR PREVENTION | Non-Final OA | The University of Chicago |
| 18492216 | METHODS OF TREATMENT OF BREAST CANCER | Non-Final OA | AstraZeneca AB |
| 17607577 | SUBSTITUTED (PIPERIDIN-1-YL)ARYL ANALOGUES FOR MODULATING AVIL ACTIVITY | Non-Final OA | University of Virginia Patent Foundation |
| 17772855 | Novel Triazolopyridine Derivatives and Pharmaceutical Composition Comprising Same | Non-Final OA | Daewoong Pharmaceutical Co., Ltd. |
| 18563916 | COMPOSITION CONTAINING HOMOHARRINGTONINE AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MUSCLE DISEASES | Non-Final OA | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY |
| 18275850 | HETEROAROMATIC SPERMIDINE ANALOGUES AND THEIR ANTICANCER ACTIVITY | Non-Final OA | FLORATEK PHARMA S.A. |
| 18473282 | ERBB/BTK INHIBITORS | Non-Final OA | Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
| 17917450 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | Final Rejection | PTC Therapeutics, Inc. |
| 17794729 | PARAXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | Final Rejection | PX ING, LLC |
| 17766149 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Non-Final OA | NOVARTIS PHARMA AG |
| 18258620 | COMBINATION THERAPIES COMPRISING OXYGEN-CONTAINING STRUCTURALLY ENHANCED FATTY ACIDS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | Non-Final OA | NORTHSEA THERAPEUTICS B.V. |
| 18036673 | SARM1 ENZYME ACTIVITY INHIBITOR AND USE THEREOF IN NEURODEGENERATIVE DISEASES | Non-Final OA | ARTIVILA BIOPHARMA |
| 18192624 | Anti-Oncogenic Phytochemicals and Methods and Uses for Treating Cancer | Non-Final OA | Ostentus Therapeutics, Inc. |
| 17439763 | METHODS OF TREATING CANCER USING TRIMETAZIDINE-BASED COMPOUNDS | Non-Final OA | IMBRIA PHARMACEUTICALS, INC. |
| 17759782 | ALPHA-HYDROXYLATED FATTY-ACID METABOLITES, MEDICAL USES AND USE AS BIOMARKERS | Final Rejection | UNIVERSITAT DE LES ILLES BALEARS |
| 17793817 | NOVEL FORMULATIONS COMPRISING CANNABIS | Final Rejection | NUTRAMAX LABORATORIES, INC. |
| 17615037 | METHODS OF TREATMENT WITH DEUTERATED ANALOGS OF D-SERINE | Non-Final OA | Sun Pharmaceuticals Industries, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy